Revolution Medicines Makes $50mil Deal

July 24, 2018
CEO Mark Goldsmith

EnterpriseWorks incubator graduate, Revolution Medicines, sold the sharing rights to one of their leading drug candidates to Sanofi for $50million.

 

Revolution Medicines started in the Research Park incubator in 2014 as the company “Midasyn” and have since graduated and relocated to California with their new name. Before moving to California the company launched as Revolution Medicines based on technology created at the University of Illinois.

 

The medicine that was sold to Sanofi will help fight cancer and inhibit the SHP2, which is an enzyme associated with many common types of cancer. Before being able to create this medicine they first had to create and utilize technology to probe and research the enzyme. This will be the first time Revolution Medicines will be testing a drug on humans.

 

Click here to read more on this news.